Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3000202 in moderate to severe systemic lupus erythematosus
2025-523488-39-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial of BI 3000202 in systemic lupus erythematosus (SLE) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: SRI-4 response at Week 32. Planned start Jun 2026; status: authorised.
02
Drugs
BI 3000202
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2025-523488-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523488-39-00.